The challenge now is to use such models while building on previous work to study the interplay between Aβ, tau pathology, neuroinflammation and neurodegeneration so as to better replicate AD phenotype with the long-term goal of achieving the promise of personalised medicine for this devastating disease. This evidence concerns the gene MAPT and Alzheimer disease.